1. Effect of alirocumab on cataracts in patients with acute coronary syndromes
- Author
-
Gaspard Suc, Gregory G. Schwartz, Shaun G. Goodman, J. Wouter Jukema, Garen Manvelian, Yann Poulouin, Robert Pordy, Michel Scemama, Michael Szarek, Ph. Gabriel Steg, and ODYSSEY OUTCOMES Investigators
- Subjects
Acute coronary syndrome ,Cataracts ,Alirocumab ,PCSK9 inhibitor ,Ophthalmology ,RE1-994 - Abstract
Abstract Background Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors reduce LDL-C below levels achieved with statins alone. We determined whether the incidence of cataracts was influenced by treatment with the PCSK9 inhibitor alirocumab versus placebo, and whether that incidence was affected by achieved LDL-C levels. Methods The ODYSSEY OUTCOMES trial (NCT01663402) compared alirocumab with placebo in 18,924 patients with recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin. Incident cataracts were pre-specified events of interest. In multivariable analysis using propensity score-matching on characteristics including cataract risk factors, incident cataracts were compared in the alirocumab and placebo groups according to LDL-C levels achieved with alirocumab. Results Over median follow-up of 2.8 years (interquartile range 2.3 − 3.4), the incidence of cataracts was similar with alirocumab (127/9462 [1.3%]) versus placebo (134/9462 [1.4%]); hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.74 − 1.20). In patients treated with alirocumab with ≥ 2 LDL-C values
- Published
- 2023
- Full Text
- View/download PDF